news 
Catalio Capital Closes Over $400 Million Fund IV
Venture capital firm Catalio Capital Management has announced the closure of its over $400 million Fund IV. This latest fund will continue the firm’s thesis of backing healthcare and biotechnology companies, a sector that has not been immune to the recent venture downturn.
Founded in 2020, Catalio Capital has already made over 100 investments, according to Pitchbook data. Notably, the new fund has already backed 16 companies, including diagnostics company PinkDX and drug discovery firm Superluminal Medicines.
The biotech market has experienced a sharp decline in fundraising over the past year, with only $12 billion raised in 2025 compared to its peak of $152.3 billion in 2023, according to Bloomberg. Despite this downturn, Catalio Capital remains committed to supporting innovative companies in these sectors.
Catalio’s Fund IV follows on the heels of a successful Fund III, which raised $381 million in 2020, and Fund II, which secured $100 million in 2019, also per Pitchbook data.
The firm has demonstrated its ability to adapt to changing market conditions while maintaining its focus on healthcare and biotechnology.
Source: techcrunch.com
